Singapore, Feb. 26 -- Olympus Corporation of Asia Pacific (APAC) has announced a milestone for its iTind device with expanded availability across major markets in the APAC region, a move in line with its commitment and purpose of making people's lives healthier, safer and more fulfilling.

Already marketed in the United States and Europe, the iTind procedure is a minimally invasive solution for the treatment of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. With a launch in Korea scheduled in March, iTind will become available in sixmarkets across APAC.

"With our upcoming launch in Korea, achieving wider availability of the iTind device in APAC is an important milestone for physicians and patients in our region. ...